Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes

Xiaohui Pan1,2†, Shibing Tao1,3† and Nanwei Tong1,2*

1 Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China, 2 Laboratory of Diabetes and Islet Transplantation, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, China, 3 Department of Endocrinology, Ziyang First People’s Hospital, Ziyang, China

Neurotransmitters are signaling molecules secreted by neurons to coordinate communication and proper function among different sections in the central neural system (CNS) by binding with different receptors. Some neurotransmitters as well as their receptors are found in pancreatic islets and are involved in the regulation of glucose homeostasis. Neurotransmitters can act with their receptors in pancreatic islets to stimulate or inhibit the secretion of insulin (β cell), glucagon (α cell) or somatostatin (δ cell). Neurotransmitter receptors are either G-protein coupled receptors or ligand-gated channels, their effects on blood glucose are mainly decided by the number and location of them in islets. Dysfunction of neurotransmitters receptors in islets is involved in the development of β cell dysfunction and type 2 diabetes (T2D). Therapies targeting different transmitter systems have great potential in the prevention and treatment of T2D and other metabolic diseases.

Keywords: glucose homeostasis, neurotransmitters, neurotransmitter receptor, pancreatic islets, type 2 diabetes

INTRODUCTION

Glucose homeostasis is critical for life maintenance, and the normal glucose ranges for the body are set by the biological defended level of glycemia (BDG) in the central nervous system (CNS). The neuronal populations in the arcuate nucleus of the hypothalamus are crucial for the regulation of energy balance, primarily in the control of food intake (i.e., appetite), which makes the CNS an indispensable part of metabolism (1). The pancreatic islets are key parts of glucose homeostasis. Pancreatic β cells are the only source of the glucose-lowering hormone insulin in the body. Dysfunction of β cells leads to impaired or insufficient insulin secretion, which results in hyperglycemia and diabetes. Nutrients in circulation, such as glucose, fatty acids and amino acids, can act on islets directly or indirectly to modulate the secretion of hormones from islets to regulate blood glucose.

Glucose is the most important insulin secretagogue. When blood glucose is higher than the Km of glucose transporters on the β cell membrane, they work to take up glucose into cells. The metabolism of glucose generates adenosine triphosphate (ATP), resulting in closure of ATP-sensitive K+ channels (KATP) to trigger membrane depolarization, electrical activity and opening of voltage-dependent Ca2+ channels (VDCCs), increasing the intracellular Ca2+ concentration ([Ca2+]i).
and initiating exocytosis of insulin granules (2, 3). The other cells in the islets share a similar secretion pattern and play roles in the maintenance of glucose homeostasis. The α cells of the pancreatic islets secrete glucagon to raise blood glucose in response to hypoglycemia, and the δ cells secrete somatostatin to inhibit the secretion of both insulin and glucagon. Appropriate communication within the islets as well as between islets and other organs is needed to maintain glucose homeostasis under different situations (4).

Neurotransmitters are a group of signaling molecules secreted by neurons that modulate the function of the nervous system, including amino acids, monoamines, peptides, and purines (5). The blood–brain barrier (BBB) restricts the communication of neurotransmitters between the CNS and periphery to keep the brain functioning correctly. The islet is a mini-organ vascularized and innervated substantially, and CNS-derived neurotransmitters can function on islets through sympathetic and parasympathetic nerves (6, 7). Moreover, neurotransmitters in the CNS can also be synthesized in the periphery, including islets, and regulate insulin secretion in a glucose-dependent or glucose-independent manner to maintain glucose homeostasis. Upon binding with corresponding receptors on the membrane, the signaling molecules exert stimulatory or inhibitory effects on hormones secretion. There are two major types of neurotransmitter receptors: ionotropic receptors and metabotropic receptors (8). Ionotropic receptors provide ligand-gated channels for ions and alter the membrane potential to excite or inhibit cell activity. Most metabotropic receptors are G protein-coupled receptors (GPCRs), which rely on second messengers inside the cell to modulate ion channels or trigger signaling cascades to release calcium from cells (9).

Functional GPCRs can be divided into four families depending on the α subunit type: the G_{αs} family, G_{αi/G}G_{αo} family, G_{αq/11} family, and G_{αt12/G}G_{αt3} family. The G_{αs} and G_{αt/o} pathways target the cyclic adenosine monophosphate (cAMP)-generating enzyme adenyl cyclase (AC) to stimulate or inhibit the conversion of cytosolic ATP to cAMP. Cytosolic cAMP determines the activities of ion channels and is considered a second messenger of GPCRs. The effector of the G_{αq/11} pathway is phospholipase C-β, which produces the second messengers inositol (1,4,5) trisphosphate (IP3) and diacylglycerol (DAG) to increase cytosolic Ca^{2+} levels.

The pancreatic islets are key parts of glucose homeostasis. Appropriate communication between islets and other organs is needed to maintain glucose homeostasis under different situations (4).

The neuronal populations in the arcuate nucleus of the hypothalamus are crucial for the regulation of energy balance, primarily in the control of food intake. In addition, the normal glucose ranges are set by the biological defended level of glycemia (BDLG) in the central nervous system (CNS) (1). Nutrients in circulation, such as glucose, fatty acids and amino acids, can act on islets directly or indirectly to modulate the secretion of hormones from islets to regulate glucose levels. The endocrine cells in islets (α, β and δ cells) share the same vesicular formation and secretion mechanisms as those in the CNS.

In this paper, we will review the function of neurotransmitters and their related receptors in islets and their roles in the development of type 2 diabetes (T2D), and discuss their potential in the treatment of T2D and other metabolic diseases.

**AMINO ACIDS**

**Glutamate**

Glutamate is a nonessential amino acid in the body and a primary excitatory neurotransmitter in the CNS (10). Glutamate is synthesized in most tissues and is contained in many foods. Intracellular glutamate is formed in mitochondria by glutamate dehydrogenase (GDH) or in the cytosol with the malate-aspartate shuttle (MA). In islets, glutamate mainly comes from α cells, and glutamate infiltration from blood through vessels is insignificant (11). Once formed, intracellular glutamate can be loaded into secretory granules by vesicular glutamate transporter 2 (VGLUT2) and released with glucagon under low-glucose conditions (12).

The glutamate receptors include ionotropic receptors N-methyl-D-aspartate (NMDA) receptors and non-NMDA receptors and metabotropic receptors named mGluR1-8. NMDA receptors can be activated by glycine and glutamate, regulating intracellular sodium and calcium balance. Non-NMDA receptors, including α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors and kainate receptors, mediate fast excitatory synaptic transmission. In islets, NMDA receptors are expressed on β cells, and non-NMDA or AMPA/ kainate receptors are expressed on α and δ cells. The activation of NMDA receptors on β cells facilitates calcium influx and induces transient insulin secretion. However, the net effect of NMDA receptor activation is inhibiting repolarization after depolarization, resulting in inhibited glucose-stimulated insulin secretion (GSIS). Continuous NMDA receptor activation causes excitotoxicity and death of neurons in the CNS, so does β cells in islets (13). Inhibition of NMDA receptors can enhance GSIS and increase insulin content in islets to improve glucose tolerance in mice (14, 15). AMPA/kainate receptors have less affinity for glutamate than NMDA receptors, and they mediate the excitatory effect of glutamate on neurons in the CNS and α cells in islets. Glutamine is an amino acid with known glucagonotropic effects. Activation of AMPA/kainite receptors on α cells induces influxes of sodium and calcium, leading to depolarization and secretion of glucagon along with intracellular glutamate. The released glutamate can bind with AMPA/kainate receptors again to form a positive feedback loop for glucagon secretion (15, 16). Rat δ cells express the AMPA receptor, and glutamate induces somatostatin release from δ cells under low-glucose conditions, inhibits the secretion of glutamate and glucagon from α cells and forms negative feedback in islets (17).

The mGluRs and related GPCRs have also been shown to regulate islet function, in addition to their roles in the CNS and diabetic neuropathy (18). Group I mGluRs (mGluR1,5) belong to the G_{αi/11} family, and group II mGluRs (mGluR2,3) and group III mGluRs (mGluR4,6,7,8) belong to the G_{αt/o} and G_{αs} families, respectively. The mGluR4 was identified in rat islets and plays a role in PP cells as well as α cells (19, 20). The mGluR8 was detected in male Wistar rat islets, rodent insulin-secreted cell lines RINm5F and MIN6 cells (20), in which the specific agonist
of group III receptors inhibited insulin release. However, mGluR8 is also present in α cells of female Sprague–Dawley rats, and the mGluR8 agonist inhibited glucagon release; the group III receptor antagonist reduced this effect (21). The mGluR3 and mGluR5 were detected in rat and human islets (20), and agonists specific to group I or group II increased the release of insulin. The mGluR5 was shown to functionally interact with NMDARs and is needed for optimal insulin secretion (22). The expression of mGluRs in other cells of islets and their function needs further research.

Plasma glutamate levels are elevated in many chronic oxidative stress conditions, such as obesity, insulin resistance, diabetes and cancer (23), and in acute injuries, such as head trauma or cerebral ischemia, creating excitotoxicity and facilitating inflammation (24). Prolonged high glutamate levels accelerate the onset of T2D and increase the risks of cardiovascular diseases in obesity and T2D patients (25, 26).

Type 1 diabetes (T1D) patients have higher glutamate levels in their brains, which can be used as an early marker of diabetes-related neurodegenerative diseases (27). Recently, therapies targeting glutamate receptors have been developed to treat T2D. NMDAR antagonists, such as dextromethorphan (DXM), amantadine and memantine, have been successfully used in the treatment of many diseases for decades, including nonproductive cough, nonketotic hyperglycemia, Parkinson’s disease, and Alzheimer’s disease (28). DXM was proven to improve insulin secretion and glycemic control in T2D patients (14, 29). The DXM derivative Lam39M increased the duration and frequency of Ca2+ oscillations, extended the time of insulin secretion, and agonists specific to group I or group II increased the duration and frequency secretion and glycemic control in T2D patients (14, 29). Lam39M also has lower penetration to the BBB, minimizing the protected mouse and human pancreatic islets from cell death. The islets of rats and human and MIN6 cells, and the GABA B receptor agonist inhibited the release of insulin in the presence of 25 mmol/l glucose (20, 41). Knockout of the GABAB receptor improved glucose tolerance and increased insulin content in the islets of mice, but constitutive absence of the GABAB receptor induced insulin resistance in mice (42).

The GABA content in islets of T2D patients and animals is lower than normal, accompanied by β cell dysfunction and lower insulin content (43). The presence of GAD autoantibodies is important for the diagnosis of autoimmune diabetes (44). In addition to endocrine cells in islets, GABA also works on innate immune cells such as T cells, inhibiting NF-kB signaling and protecting β cells from inflammation, especially in conditions such as T1D and islet transplantations (45).

**Gamma-Aminobutyric Acid**

Gamma-aminobutyric acid (GABA) is synthesized by glutamate and glutamate decarboxylase (GAD) in GABAergic neurons and is the most important inhibitory neurotransmitter in the mammalian CNS. *Bacteroides* in the gut are the main source of GABA in the periphery (31). Although the BBB separates peripheral GABA from the CNS, supplemental GABA or precursors of GABA can orally feedback to the CNS through the enteric nervous system (ENS) (32) and GABA receptors on adrenergic and cholinergic nerves (33, 34).

The islet has a density of GABA and GABA receptors comparable to that of the CNS (35). The receptors of GABA include the ligand-gated ion channel GABA_A and the GPCR member GABA_B. GABA_A activation induces chloride influx, inhibiting depolarization and reducing excitability of target cells. GABA_B couples with the G_s protein and inhibits cAMP production to exert an inhibitory effect.

The GABA in islets is supplied by β cells by the time of insulin secretion (36). The simultaneously released GABA can bind with GABA_A receptors on β cells to inhibit insulin secretion as an autocrine signal. Activation of GABA_A receptors also enhanced proliferation of β cells (37). Meanwhile, GABA from β cells can inhibit glucagon secretion and cell proliferation by binding with GABA_A receptors on α cells as a paracrine signal (38). When the glucose level is not high enough to evoke action potentials on membranes of β cells, the chloride potential made by the GABA_A receptor can moderately depolarize β cells to induce insulin and GABA release (39), but when the glucose level is higher than BDLc, GABA will inhibit excessive release of insulin (40). It has been reported that human δ cells express GABA_A receptors and that the GABA_A antagonist SR95531 reduces the secretion of somatostatin at different glucose concentrations (39).

The mRNAs of GABA_B receptors 1 and 2 were identified in islets of rats and human and MIN6 cells, and the GABA_B receptor agonist inhibited the release of insulin in the presence of 25 mmol/l glucose (20, 41). Knockout of the GABA_B receptor improved glucose tolerance and increased insulin content in the islets of mice, but constitutive absence of the GABA_B receptor induced insulin resistance in mice (42).

**Glycine**

Glycine is the simplest stable amino acid acting as an inhibitory neurotransmitter in the CNS (46). The glycine level in human cerebrospinal fluid is 5 μM but increases to 150-400 μM in blood. Extracellular glycine can bind with glycine receptors (GlyRs) or be transported into cells by glycine transporters (GlyTs). GlyR is an ionotropic receptor that mediates the transport of chloride. Both GlyR and GlyT are expressed on α cells and β cells of human islets but are barely detected in rodents (47, 48). Although glycine inhibits the activity of neurons in the CNS, it actually excites β cells in islets due to different intracellular chloride concentrations (7 mM in neurons and 32 mM in β cells). Glycine induced depolarization and increased intracellular calcium in β cells (47).

Glycine can be coreleased with insulin, and insulin can enhance the effect of glycine-activated current (47, 49). In α cells of islets, glycine can induce glucagon secretion in vitro and in vivo without a significant change in insulin levels (48, 50). Moreover, glycine can bind with and saturate NMDA receptors as an endogenous antagonist (51), block the excitotoxic effect of glutamate and help maintain normal GSIS (14, 15).

The lower glycine levels in circulation are related to obesity, diabetes and nonalcoholic fatty liver disease (NAFLD), and GlyR expression and glycine-induced currents on β cells of T2D patients is also reduced (52, 53). Supplementation with glycine can alleviate oxidative stress, lower blood pressure, and reduce risks for T2D (54). The elevation of glycine might be protective for people with higher metabolic risks.

**D-Amino Acids**

Natural amino acids can be divided into L-type and D-type based on their chirality (except glycine). D-amino acids can be derived
Dysregulation of Monoamine Neurotransmitters (MNTs) is a primary cause of mental diseases. MNTs, including serotonin, norepinephrine, dopamine and histamine, exist broadly in the CNS and peripheral nervous systems, including the brain stem, spinal cord, enteric nervous system, and peripheral nerves. Dysregulation of MNTs is a primary cause of mental diseases.

Serotonin
Tryptophan is processed by tryptophan hydroxylase (TPH) and aromatic-L-amino acid decarboxylase (AADC) to form 5-hydroxytryptamine (5-HT, serotonin) in the CNS and intestines. Enterochromaffin cells (ECCs) contribute approximately 90% of 5-HT in the body, and the others function separately due to the existence of the BBB (70). The receptors of 5-HT belong to GPCRs except 5-HT receptor 3 (5-HT3R), which is a ligand-gated ion channel.

D-Asp is a racemase product of L-aspartate and a precursor of NMDA and is located at the pineal gland and pituitary in the CNS and adrenal gland (56). D-Asp can stimulate hormone secretion from pituitary glands and the hypothalamus (57). Hyperglycemia can induce the release of D-Asp from the retina of diabetic rats and is related to diabetic retinopathy (58). Although D-Asp is found in α cells and can be released from the rat insulinoma cell line INS-1 along with insulin (59, 60), the function of D-Asp in islets is unclear.

D-Ser is a neurotransmitter derived from serine under serine racemase (SRR) in the CNS. D-Ser can inhibit high-fat diet consumption and reduce body weight in mice (61). The content of D-Ser is highest in the CNS, others are also present in the liver, kidney and pancreas (62). The key enzyme of D-Ser synthesis, SRR, is expressed in β cells of human and mouse (63). SRR-knockout mice (Srr-KO) have similar D-Ser content but less insulin content in the pancreas than wild-type (WT) mice (64). Srr-KO mice have lower blood glucose and fasting insulin levels and better glucose tolerance and insulin sensitivity (65). D-Ser acts as a coactivator of NMDA receptors in the CNS, and deletion of SRR in the brain impairs the function of NMDA receptors. Not surprisingly, Srr-KO mice have fewer NMDA receptors on islets, and the NMDA receptor antagonist MK-801 failed to suppress insulin secretion in the islets of Srr-KO mice (65).

A high D-Ser diet increases D-Ser levels in blood and leads to hyperglycemia and impaired glucose tolerance in mice, which can be blocked by α2-adrenergic receptor antagonists (61). Therefore, the adrenergic system might participate in the effect of D-Ser in islets. Polymorphisms of the SRR gene are associated with T2D susceptibility (66) and metformin efficiency (67). Thus researches on the metabolism and effects of D-amino acids are worthwhile in the treatment of T2D.

Catecholamine
Catecholamine (CA) is a group of chemicals synthesized from phenylalanine or tyrosine in the central and peripheral nervous systems, including dopamine, epinephrine and norepinephrine.

Dopamine comes mainly from dopaminergic neurons in the substantia nigra and ventral tegmental area in the CNS and peripheral nerves, the adrenal medulla and some neuroendocrine cells are the main sources of dopamine in the periphery (81). Norepinephrine is synthesized and released by the locus coeruleus in the CNS and sympathetic nerves in the periphery. Epinephrine is released from the adrenal gland and some neurons in the brain stem. Both α and β cells in islets of humans and rodents possess enzymes of CA synthesis and specific transporters for CAs, which means they could be possible sources of CAs in islets (82).

The receptors of CAs are GPCRs. The CAs couple with Gs or Gi subunits to induce excitation and inhibition, respectively. The excitatory receptors increasing cAMP concentration include the D1 and D5 dopamine receptors and the α1, β1, β2 and β3 adrenergic receptors. The inhibitory receptors D2, D3 and D4 dopamine receptors, the α2 adrenergic receptors, reduce the cAMP level in cells (83).

The dopamine receptors D1, D5 (82, 84) and the adrenergic receptor α2 are expressed on β cells (85), while the dopamine receptors D2 and D3 (82) and the adrenergic receptors α1, β1, and β2 are expressed on α cells (86, 87). The effects of dopamine and norepinephrine on islets are inhibiting insulin secretion and promoting glucagon secretion (87, 88). The activation of α2...
adrenergic receptors on β cells can suppress insulin secretion, insulin gene expression and insulin synthesis (89, 90). There is clear evidence that overexpression of α2 adrenergic receptors in rodent β cells causes impaired insulin secretion and is associated with spontaneous onset of T2D in GK rats and increased risk of T2D in human (91, 92). Knockout of the α2 adrenergic receptor in mice showed lower blood glucose levels and higher plasma insulin levels, as well as improved glucose tolerance, than the wild type (93). A high level of dopamine inhibits β cell proliferation and induces apoptosis of β cells (94). However, dopamine is necessary for the survival and development of islets, and mice lacking synthesis enzymes or receptors of dopamine develop glucose intolerance and impaired GSIS early in their life (95). β3 adrenergic receptors exist on adipose tissue and induce lipolysis and fatty acid production upon activation (96).

The dopamine transporter (DAT) is located on the surface of β cells. DAT can take up dopamine and store them in vesicles together with intracellularly synthesized dopamine with the help of VMAT2. When β cells depolarize and secrete insulin, dopamine will act on dopamine receptors and adrenergic receptors to inhibit insulin release as an autocrine signal in negative feedback (97).

Bromocriptine is a dopamine D2 receptor agonist used in the treatment of Parkinson’s disease and hyperprolactinemia. Additionally, it has been used as a central antidiabetic drug for years and is still recommended by the American Diabetes Association (ADA) in the latest guidelines (98). Bromocriptine can cause metabolic alterations in patients with insulin resistance and obesity by resetting the hypothalamic circadian rhythm of monoamine neuronal activities. The agonistic action of dopamine may reduce the hypothalamic drive for increased lipid and hepatic glucose production and insulin resistance (99). Elevated prolactin levels are frequently associated with weight gain and obesity, which are common in hyperprolactinemia patients (100). Bromocriptine has the ability to suppress prolactin levels, thereby augmenting glucose tolerance and regulating GSIS (99).

The adrenergic nerve system is activated under stresses such as cold, nervousness and hypoglycemia, promoting heat generation, glucose supplementation, lipolysis and glycolysis. The α cell is able to synthesize and release dopamine and norepinephrine and stimulate glucagon secretion by binding with the adrenergic β1 receptors themselves (82). The autocrine, paracrine and nerve-derived signals in islets can partly explain the higher risk of T2D under prolonged stresses.

T2D patients have higher norepinephrine levels in blood, which inhibits the secretion of insulin (101) and impairs the responsiveness of β cells to adrenergic signals (102). Insulin resistance is characterized by a higher insulin level in the periphery, which will inhibit the reuptake of CAs and activate adrenergic receptors on α and β cells constantly, resulting in damage to glucose homeostasis and accelerating the progression to T2D (79, 103).

Pheochromocytoma is a rare neuroendocrine tumor capable of producing CAs. Hyperglycemia is a common metabolic dysfunction of Pheochromocytoma patients, mostly because of impaired insulin secretion and insulin sensitivity. Epinephrine and norepinephrine disturb glucose homeostasis in different ways. Epinephrin tends to impair insulin secretion, while norepinephrine tends to promote insulin resistance (104). The metabolic mechanism of hyperglycemia in Pheochromocytoma patients depends on the dominant CAs released by Pheochromocytoma and the distribution of adrenergic receptors (105). In addition, it has been reported that the Pheochromocytoma cell line PC12 is rich in D-Asp (62), which can inhibit GSIS by acting on NMDA receptors on β cells (14, 15).

**Histamine**

Histamine is synthesized from histidine by histidine decarboxylase (HDC) and stored in mast cells and basophils in an inactive form. The tuberomammillary nucleus (TMN) neurons expressing HDC are the primary source of histamine in the CNS, and the parietal cells in the stomach also express HDC and secrete histamine. mast cell-derived histamine is scarce in the CNS and periphery under normal conditions (106).

Histamine receptors (HRs), including H1-4, are GPCRs with potential ion ligand-gated channel activity. H1R couples with the Gq/11 subunit to induce calcium current and cell excitation. H2R and H3R are inhibitory receptors that bind the Gi and Gq/o subunits, respectively. HDC is expressed in α and β cells in islets, but is more highly expressed in tumors (107). The main sources of histamine in islets are mast cells and basophils.

H1R, H2R and H3R are expressed in islet β cells of human and rodents (88, 108). The general effect of histamine on β cells is inhibition of insulin secretion and cell proliferation (109). Agonists of H1R can facilitate insulin secretion and partially counteract cytokine-induced β cell destruction (108, 110). The first generation of the antihistamine drug trimeprazine can incompletely activate H1R and increase β cell proliferation in mice (111). The H1R antagonist cetirizine did not affect diabetes development in NOD mice but did improve the glucose tolerance of high-fat diet-fed mice (112). A selective H3R inverse agonist, JNJ-5207852, facilitates insulin secretion and possibly promotes β cell proliferation, while a selective H3R agonist inhibits insulin secretion and cell proliferation of MIN6 cells (108). Both agonists and antagonists of H2R can inhibit insulin secretion, possibly due to species variation and different receptor distributions (88, 108). H3R is expressed on α cells in islets and can inhibit glucagon release (113). Although direct evidence of H4R expression in islets is lacking, blocking H4R with its selective antagonist JNJ-39758979 was efficient in the prevention of diabetic nephropathy progression (114), possibly by inhibiting inflammatory activities in tissues.

Chronic H3R agonist treatment shows multiple metabolic benefits in mice with diet-induced obesity (DIO), such as reducing food intake and body weight and alleviating hyperleptinemia and hyperinsulinemia (115). Proxyfan is an H3R protean agonist that can be used as an agonist, inverse agonist and antagonist of H3R. In T2D mice, oral administration of Proxyfan can lower blood glucose and glycosylated hemoglobin Alc (HbAlc), and intracerebroventricular administration of Proxyfan can increase plasma insulin levels via a glucose-independent mechanism (116).

Systemic histaminergic activity is elevated in T2D patients and animals (117). Reactive oxygen species (ROS) are necessary...
for histamine release, and hyperglycemia can increase ROS and might contribute to the higher histamine levels in T2D patients (118). Higher histamine levels in the plasma of T2D patients also accelerate vascular injury, especially in the aorta, increasing the risk of cardiovascular diseases (119). The islets of T1D patients and streptozotocin-induced diabetic animals have significant mast cell infiltration, and the histamine released by mast cells can aggravate immune injury and lead to cell death through the caspase pathway (120). H2R antagonists are widely used as antacid agents to treat peptic ulcers, and H2R antagonist treatment is associated with a lower prevalence of NAFLD in men (121). It is possible that they have antioxidant properties and direct effects on inflammatory cells, including monocytes, which might prevent inflammation. However, prolonged treatment with H2R antagonists increases the risk of T2D in peptic ulcer patients (122, 123).

**ACETYLCHOLINE**

Acetylcholine (ACh) is a product of choline and acetyl-coenzyme A (CoA), synthesized by choline acetyltransferase (ChAT) and stored by vesicular acetylcholine transporter (vAChT) in the CNS cholinergic neurons and peripheral autonomic nervous system (sympathetic and parasympathetic nerves). The ACh in islets mainly comes from cholinergic nerve terminals in rodents but comes from both nerves and α cells in humans. The ACh in α cells is loaded into different vesicles from glucagon by vAChT so that they can be released separately (124, 125). The α cells are scattered in human islets but are located on the boundary of islets in rodents, which facilitates paracrine ACh signals from α cells passing to neighboring cells easily in human islets.

Cholinergic receptors can be divided into muscarinic (M) and nicotinic (N) receptors. M-type receptors (mAChRs) are GPCRs that couple with the G_q/11 (M1, M3, M5) or G_i/o (M2, M4) subunits to induce excitatory or inhibitory effects on cells. The N-type receptors (nAChRs) are a ligand-gated ion channel consisting of subunits.

The M3 and M5 receptors are present on β cells and can increase insulin release upon activation (124). M3 receptor-deficient mice displayed lower glucagon and insulin levels and impaired postprandial insulin release (126). Decreased expression of M3 receptors in islets was observed under hyperglycemic conditions both in vivo and in vitro (127). These results suggest the therapeutic potential of the M3 receptor. In addition, ACh can also be involved in paracrine regulation within islets indirectly, which increases or reduces the secretion of somatostatin by binding with M1 receptors on δ cells of human or (128) with M3 and M4 receptors on δ cells of mice (129). The effects mediated by nAChRs are much more complex than those mediated by mAChRs. Isoforms of nAChRs, including α2, α3, α4, α5, α7, β2, and β4 subunits, assemble to form functional nAChRs. The predominant subunits expressed in islets are α5 and β2 in human, α7 and β2 in rodents (130, 131). Nicotine is a natural agonist of nAChRs. Smoking is one of the most famous risk factors for T2D (132). However, chronically treating db/db mice with a small amount of nicotine could improve glucose metabolism and insulin sensitivity (133). The activation of nAChRs can increase β cell mass and enhance insulin secretion (134, 135), as well as protect β cells against cytokine toxicity (130). Loss of α5nAChR in mice was related to increased nicotine intake, of which the impact on glucose homeostasis remains unclear (136). Deletion of α7-nAChR in mice impairs glucose tolerance and causes insulin resistance (133). PUN-282987 is a selective α7-nAChR agonist capable of enhancing insulin sensitivity in muscle, liver and adipose tissue in mice and reducing inflammation via the STAT3 pathway (137). Recently, nicotine was found to act on TCF7L2 in the pineal gland and transmit nicotine signals to islets, leading to dysregulation of insulin and glucagon (138).

**PEPTIDES**

Peptide signals play a role in both endocrine and neural systems. The term “neuropeptide” is defined by small proteinaceous substances produced and released by neurons through the regulated secretory route and acting on neural substrates. Neuropeptides may act as neurotransmitters or neuromodulators and commonly bind to GPCRs to affect the activities of neurons and other tissues, including pancreatic islets (139, 140). With the help of genetics and multiomics techniques, the family of neuropeptides has expanded quickly during decades. We only discussed several members of the large family and their roles in pancreatic islets due to limited space, including glucagon-like derived peptides, including glucagon and GLP-1 (147).

Incretins are a group of metabolic hormones released after eating that augment the secretion of insulin by a blood glucose-dependent mechanism. GLP-1 and GIP are two main candidate molecules that fulfill the criteria for incretin (144). Both GLP-1 and GIP are rapidly inactivated by dipeptidyl peptidase-4 (DPP-4).

GLP-1 is secreted by preproglucagon neurons in the solitary nucleus in the CNS, regulating the activities of the hypothalamus and brain areas (145). GLP-1 in the periphery mostly comes from enteroeocnocrine L cells (146). The α cells in islets also express the preproglucagon gene and synthesize and secrete proglucagon-derived peptides, including glucagon and GLP-1 (147). The receptors of glucagon and GLP-1 share significant homology and both belong to the G family of GPCRs and are expressed on β cells in islets, which contribute to the cross-reactivity of glucagon and GLP-1 and induce insulin secretion (148, 149). GLP-1 promotes insulin synthesis and secretion upon stimulation (150) and acts synergistically with glucose to promote insulin gene transcription, mRNA stability, facilitate insulin biosynthesis to replenish insulin store and prevent exhaustion.
and apoptosis of \( \beta \) cells (151). GLP-1R agonists enhance \( \beta \) cell proliferation and expand \( \beta \) cell mass even in normoglycemic rodents (152). Some researchers also found GLP-1 receptors on \( \delta \) cells to control the release of somatostatin (153).

GIP is synthesized by K cells of the duodenum and small intestine. The GIP receptor is a \( \alpha \), family member of GPCRs widely expressed within the CNS (154), \( \alpha \) cells and \( \beta \) cells in islets (155) and white adipose tissues (156). The GIP receptor (GIPR) is expressed in similar amounts in \( \alpha \) and \( \beta \) cells. GIP stimulates glucagon secretion directly through GIPRs on \( \beta \) cells, while GIP can potentiate the release of glucagon by activating GIPRs on \( \alpha \) cells. Glucagon then binds with GLP-1R or the glucagon receptor and stimulates insulin secretion (155, 157). In addition to stimulating the secretion of insulin, such as GLP-1, GIP promotes triglyceride storage by directly activating GIP receptors on adipocytes and indirectly through the lipogenic actions of insulin (158) and enhances glucose uptake and insulin sensitivity of adipocytes, therefore improving the long-term storage of lipids by facilitating the healthy expansion of white adipose tissues (159). Our previous work found that GLP-1 levels in the plasma of T2D and prediabetes patients were lower than those in healthy people but did not differ between T2D and prediabetes patients (160). The genes encoding the human GLP-1 or GIP receptors have not been linked to enhanced genetic susceptibility to diabetes (63). GLP-1-targeted treatments can reduce body weight and risks of cardiovascular events, which are independent of glucose-lowering effects (161, 162). The new generation of anti-diabetic drugs GLP-1 receptor agonists (GLP-1RAs) have shown promising benefits on T2D treatment, as well as the DPP-4 inhibitors, which raises levels of GLP-1 and GIP to augment insulin release after a meal. Central and peripheral administration of GIP receptor agonists lowers body weight by reducing caloric intake (163, 164).

Clinical trials employing liraglutide (human GLP-1 analogue) or exenatide (exendin-4 derivates, animal GLP-1) in addition to intensified insulin regimes in T1D patients did not demonstrate convincing hypoglycemic benefits or describe potential adverse outcomes such as a higher risk of ketoacidosis. Only body weight and insulin doses were consistently reduced (165, 166). Some GLP-1RAs can improve the metabolism and function of the CNS when administered in the periphery they are strongly recommended by ADA for the treatment of T2D and might play positive roles in the treatment of neurodegenerative diseases (167).

**Cholecystokinin**

Cholecystokinin (CCK) is secreted by specialized neurons in the CNS and ENS and by enteroendocrine I cells in the intestine (168). The receptors of CCK belong to GPCRs, including CCK1 (CCKA) receptor and CCK2 (CCKB) receptor. CCK plays roles in inducing anxiety and satiety in the CNS, regulating gastric emptying and distension and gallbladder contraction in the gastrointestinal system. It is also a potent stimulator of pancreatic acinar cells that release digestive enzymes after meals (168).

The CCK1 receptor is colocalized with insulin and glucagon in the islets of pigs, rodents and human (169). Activation of CCK1 receptors initiates the Gs and Gq/11 signaling pathways in islet \( \beta \) cells under high- and low-glucose conditions, respectively (170). The biologically active fragment CCK-8 and agonists of the CCK1 receptor can induce insulin secretion and protect \( \beta \) cells against apoptosis (170, 171). CCK2 receptors were found in \( \alpha \) cells and \( \delta \) cells of islets. The CCK2 receptor is also called the gastrin receptor because another gastrointestinal peptide, gastrin, secreted by G cells in the gastric antrum shares a similar sequence with CCK and can bind to the CCK2 receptor with almost the same affinity and potency (172). Gastrin and CCK induced glucagon secretion from purified human islets, which was blocked by an antagonist of CCK2 (173).

Recently, the gene encoding cholecystokinin (Cck) was found to be expressed and upregulated in islets of obese and insulin-resistant mice. CCK was detected in both \( \alpha \) and \( \beta \) cells (174). Overexpression of CCK was able to protect \( \beta \) cells from apoptosis, while loss of CCK resulted in reduced islet size and \( \beta \) cell mass and induced a diabetogenic phenotype in mice (174, 175).

The insulinotropic and protective role of CCK in islets makes it a promising therapeutic target for T2D and obesity. Structural modiﬁed CCK analogs (such as glycated CCK8 and (pGlu-Gln)-CCK8) have been proven to suppress appetite and improve glucose tolerance and plasma lipids and reduce lipid accumulation in the pancreas and body weight in obese and diabetic rodents (176). CCK has been thought to be an incretin candidate because it originates from guts and responses to nutrients, but CCK receptor blockade failed to affect postprandial insulin secretion, like GLP-1 and GIP (177). However, CCK has the potential to reduce weight and blood glucose and could be an effective adjunct therapy for T2D (178).

**Oxytocin and Vasopressin**

Oxytocin and vasopressin have similar structures and are synthesized in the supraoptic nucleus and paraventricular nucleus of the hypothalamus, respectively. They are stored in the neurohypophysis and released upon stimulation, such as labor and hypertonicity. Peripheral OT also comes from the uterus, placenta, amnion and heart.

The receptors of VP (V1a, V1b, V2) and oxytocin are GPCRs expressed broadly in the CNS and periphery (179). The V1a, V1b and oxytocin receptors belong to the Gq/11 family and induce excitatory effects. The V1a receptor is expressed on vessels to regulate vasoconstriction, and the V1b receptor in the CNS assist the release of andrenocorticotropic hormone (ACTH). Oxytocin plays an anorexigenic role in the CNS and primarily stimulates uterine contraction and lactation in peripheral. The V2 receptor couples with the Gs subunits to control water absorption in the kidney (180).

The pancreas is unable to generate oxytocin or vasopressin but has receptors for them on \( \alpha \) and \( \beta \) cells (181, 182). The vasopressin receptor V1b is expressed both on \( \alpha \) and \( \beta \) cells and can regulate glucose homeostasis in a glucose-dependent way, which increases insulin during hyperglycemia and increases glucagon during hypoglycemia (183, 184). The structure of oxytocin is similar to vasopressin. Oxytocin can also bind with V1b on \( \alpha \) cells to induce glucagon secretion (182). V1b knockout mice present reduced fasting insulin, glucagon and blood glucose along with enhanced insulin sensitivity (185).
Oxytocin can protect β cells from metabolic stress and cytokines, promoting insulin secretion and cell proliferation (186, 187). Infusion of oxytocin can improve GSIS in healthy unpregnant humans (188), induce insulin secretion and improve glucose tolerance in DIO mice (189). In pregnant mice, oxytocin can not only initiate parturition but also increase β cell proliferation and mass (189). Gestational diabetes mellitus (GDM) patients have lower plasma oxytocin levels than healthy pregnant women, and oxytocin antagonists can impair insulin secretion and lead to the development of GDM symptoms in pregnant mice (190). Intracerebroventricular application of nanogram amounts of oxytocin causes a rise in insulin levels but can be blocked by atropine, indicating that cholinergic neurons are involved in the CNS regulation of oxytocin on glucose homeostasis (191).

T2D patients have higher vasopressin but lower oxytocin levels in plasma (185). Chronic vasopressin infusion impairs fasting glucose and glucose tolerance in lean rats, which can be observed earlier in the obese rats (184). Treatment with oxytocin can reduce food intake and body weight in human and alleviate metabolic syndromes by improve insulin resistance (192, 193). However, therapies targeting receptors of vasopressin and oxytocin or themselves for diabetes treatment might be difficult due to safety concerns, especially chronic effects on the function of neurohypophysis.

**PURINES**

Purines are basic components synthesized biologically as nucleosides in cells, functioning as energy molecules and mediating the purinergic signaling cascade by acting on purinergic receptors in the CNS and periphery (194). Adenosine, ATP and other nucleotides, such as uridine triphosphate (UDP), are ligands of purinergic receptors P1 (adenosine receptor), P2Y and P2X receptors. P1 and P2Y receptors are GPCRs, P2X receptors are ligand-gated ion channels.

The P1 receptors A1, A2A, A2B and A3 are all found in islets. A1 receptor is a Gαo member expressed in α and β cells, inhibiting secretion of glucagon and insulin upon activation (195–197). Knockout of A1 receptor mice had no significant effect on the first phase of insulin secretion, but prolonged and amplified the second phase of insulin, glucagon and somatostatin secretion (195). It is also reported that the expression of A1 receptor in α cells declined during the progression of autoimmune diabetes and contributed to the hyperglucagonemia in prediabetic NOD mice (198). The role of another Gαo member A3 receptor in islets is unclear, possibly involved in the survival of β cells (197). A2A receptor and A2B receptor belong to Gβγ family. Activation of A2B induce insulin release in islets of rodents (199). However, the effect of A2A receptor showed species heterogeneity, which is increasing insulin secretion in mice but suppressing insulin secretion in rat β cell lines upon activation (200, 201). While in the islets of zebrafish, the nonselective adenosine receptor agonist 5’-N-ethylcarboxamidoadenosine (NECA) was found to increase the proliferation of β cells (202).

The P2Y receptors are highly conserved across species, eight P2Y receptors have been discovered in human and six of them are expressed in the islets of either human or rodents, which are P2Y1, P2Y4, P2Y6, P2Y11, P2Y13 and P2Y14 (196, 203–208). Nucleotides including purines and pyrimidines are ligands of P2Y receptors (209). Activation of P2Y1 and P2Y6 receptors increased insulin secretion in MIN6 cells (203), P2Y6 agonist MRS 2957 induced insulin secretion at high glucose concentrations (16.7 mM) (206). P2Y13 antagonist MRS2211 increased the secretion of both insulin and glucagon independent of glucose concentrations (204).

All of the known subunits of P2X receptors (P2X1-7) have been found in islets β cell of human and/or rodent (207, 210–214), the P2X7 was also found in α cells of human and mice (207, 210, 215). Activation of P2X2 receptors induces insulin secretion from β cells. ATP is the ligand of P2X receptors, which is generated during glucose metabolism within cells and is co-released with insulin from β cells (2). Therefore ATP plays an autocrine or paracrine role via P2X receptors in the islets (216). The expression of P2X2 receptors can be various in different developmental and functional state of the islets. The P2X1 and P2X4 receptors in islets of mice only emerged after birth and progressively upregulated with age (210). The P2X7 receptors in β cells of islets were upregulated in non-diabetic obese human compared with the leans possibly as a compensation, but undetectable in T2D patients (215). It is reasonable to consider P2X7 receptor a promising target for treatment of obesity and T2D (217).

**SUMMARY AND DISCUSSION**

Signals from the central and peripheral nervous systems act on islets collaboratively to maintain glucose homeostasis, which is critical for life. The isolated islets are unable to survive for a long time without the regulation of transmitters and fail to proliferate and secrete insulin, which is also an obstacle for islet transplantation therapies (218, 219). The dysregulation of signals in the CNS can impair BDLC, and push the onset of T2D (4). Obesity and glucose dysregulation are common side effects of antipsychotic drugs, which bring a higher risk of developing T2D (80).

Here, we review the evidence of the neurotransmitters presented out of the CNS and their roles in the glucose homeostasis, especially the transmitters that can be synthesized in the islets and their corresponding receptors expressed on cells in islets (Supplementary Table 1). With developments in imaging skills and multomics methods, our understanding of transmitters in organisms has been expanded largely during the past decades (220, 221). As a matter of course, the transmitters synthesized by islets also function on the CNS as feedback signals, such as 5-HT and insulin (222, 223), but the specific mechanism needs further study.

Signal molecules in the CNS and periphery are promising treatment targets for many diseases. It is known that T2D is a metabolic disease caused by multiple risk factors. Hyperglycemia, which is a marker of T2D, can be found in various physiological and pathological conditions. Islet dysfunction in diabetes also
promotes the progression of neurodegeneration (224). The success of GLP-1RAs is a good example of transmitter-targeted therapy (161, 162).

The gut-brain axis is a hotspot of research on glucose homeostasis, especially for a great variety of peripheral transmitters are derived from the intestines, not only endocrine cells but also bacteria capable of producing multiple neurotransmitters in the gut, such as dopamine, norepinephrine and GABA (225), which can act on both the central and peripheral regions (225). It is not surprising that some medicines for the digestive system also influence the metabolic system (122). The germ-free mice display increased turnover rates of dopamine, norepinephrine and serotonin in the brain, which could generally reduce pools in systemic circulation independent of microbial production (although factors influencing that increased turnover rate remain to be determined) (226). It is not surprising that some medicines for the digestive system also influence the metabolic system (122). Supplementation with GABA or glycine or the consumption of natural products such as resveratrol, which can influence GLP-1 and 5-HT levels in the peripheral and brain-gut axes, are beneficial to glucose homeostasis and could lower oxidative stress (32, 54, 227). Except for GLP-1, GABA and 5-HT, the intestine secretes dozens of other hormones that probably interact with the CNS to regulate glucose homeostasis, such as GIP, CCK, ghrelin, and peptide YY. The relationship between intestine-derived hormones and metabolic conditions deserves more attention and should be a promising therapeutic target for the treatment of both metabolic diseases and neural diseases.

Therapies targeting on more than one signaling molecules may bring more benefits. For example, LY3298176, a novel dual GIP and GLP-1 receptor agonist developed for the treatment of T2D, has been proven to improve glucose control and reduce body weight in T2D mice and humans (228) Another dual agonist is GEPP4, a weight-loss drug acting on both receptors of GLP-1 and peptide YY, which performs better than each single drug and has less unfavorable gastrointestinal reactions (229). Direct supplementation of GABA with sitagliptin (a DPP-4 inhibitor) in T2D patients can promote β cell proliferation and protect cells against apoptosis (230). Recently, the GLP-1/GIP/Glucagon receptor triagonist SAR441255 has been proven effective in glycemic control and weight loss in humans (231). These findings show great potentials of multitarget therapies in the treatment of T2D and obesity and encourage the development of more multitarget therapies in the future. Remarkably, there is interaction among different neurotransmitters and their receptors, for example, L-cells cosecrete ATP together with GLP-1 and PYY, and ATP acts as an additional signal triggering vagal activation and potentially synergizes with the actions of locally elevated peptide hormone concentrations (232). The cross reactivities among neurotransmitter signals expand their effects, clarifying the detail procedures of their interaction can promote the development of new therapies with higher efficiency and less side effects. In addition to drugs, implanted devices directly acting on nerves also find their way in the field. Implantable vagal nerve stimulators (IVNSs) have been approved by the Food and Drug Administration (FDA) to treat epilepsy and depression, which can manipulate target tissues more precisely than planted in the CNS (233, 234). In obesity and T2D patients, the application of IVNSs has also improve glucose homeostasis (235).

Research on transmitters in the central and peripheral nervous systems can extend our understanding of neurodegenerative diseases, mental diseases and metabolic diseases, assisting in disease prevention and the development of new antipsychotic drugs with higher selectivity and fewer side metabolic effects. New therapies based on the function of neural transmitters and corresponding receptors targeting pancreatic islets or beyond are also promising for the treatment of T2D and other metabolic diseases.

**AUTHOR CONTRIBUTIONS**

XP and ST reviewed the literature and wrote the manuscript. NT guided critical discussion of the topic and reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

This work is supported by grants from the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (No. ZYGD 18017). We sincerely thank Shishi Xu for help in discussion of the manuscript.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.884549/full#supplementary-material
22. Storto M, Capobianco L, Battaglia G, Molinaro G, Gradini R, Riozzi B, et al. Evidence Against a Role of EAAT2 in Pancreatic Insulin Secretion in Mice. *J Biol Chem* (2014) 289(3):1329–44. doi: 10.1074/jbc.M113.295065

25. Liu X, Zheng Y, Guasch-Ferre I, et al. NMDA Receptors in Rodent Diabetes. *Sci Rep* (2019) 9:1006. doi: 10.1038/s42255-019-0135-7

26. Palmer ND, Stevens RD, Antinuzzi PA, Anderson A, Bergman RN, Wagenknecht LE, et al. Metabolic Profile Associated With Insulin Resistance and Conversion to Diabetes in the Insulin Resistance Atherosclerosis Study. *J Clin Endocrinol Metab* (2015) 100(3):E463–E8. doi: 10.1210/jc.2014-2537

27. Wiegers EC, Rooijackers HM, van Asten JJA, Tack CJ, Heerschap A, de Galan BE, et al. Elevated Brain Glutamate Levels in Type 1 Diabetes: Correlations With Glycaemic Control and Age of Disease Onset But Not With Hypoglycaemia Awareness Status. *Diabetologia* (2019) 62(6):1065–73. doi: 10.1007/s00125-019-4682-9

28. Kalia LV, Kalia SK, Salter MW. NMDA Receptors in Clinical Neurology: Excitatory Times Ahead. *Lancet Neurol* (2008) 7(8):742–55. doi: 10.1016/S1474-4422(08)70165-0

29. Welter S, Klüppel C, Mrugula J, Wörmeyer L, Meissner T, Mayatepek E, et al. NMDAR Antagonists for the Treatment of Diabetes Mellitus–Current Status and Future Directions. *Diabetes Obes Metab* (2017) 19(Suppl 1):95–106. doi: 10.1111/dob.13017

30. Scholz O, Otter S, Welters A, Wörmeyer L, Dolenšek J, Klemen MS, et al. Peripherally Active Dextromethorphan Derivatives Lower Blood Glucose Levels by Targeting Pancreatic Islets. *Cell Chem Biol* (2021) 28(10):1484–8. doi: 10.1016/j.chembiol.2021.05.011

31. Strandwitz P, Kim KH, Terekhova D, Liu JK, Sharma A, Levering J, et al. GABA-Medulating Bacteria of the Human Gut Microbiota. *Nat Microbiol* (2019) 4(3):396–403. doi: 10.1038/s41564-018-03073-3

32. Boonstra E, de Kleijn R, Colzato LS, Alkemade A, Forstmann BU, Nieuwenhuis S. Neurotransmitters as Food Supplements: The Effects of GABA on Brain and Behavior. *Front Psychol* (2015) 6:1520. doi: 10.3389/fpsyg.2015.01520

33. Shah A, Li Y, Yin J, Hu H, Xue M, Li X, et al. A Novel Sympathetic Neuron GABAergic Signalling System Regulates NE Release to Prevent Ventricular Arrhythmias After Acute Myocardial Infarction. *Acta Physiol* (Oxf) (2019) 227(2):e13315. doi: 10.1111/apha.13315

34. Maloumouz A, Ilyin V, Nikolovsky E. Components of the GABAergic Signaling in the Peripheral Cholinergic Synapses of Vertebrates: A Review. *Amino Acids* (2019) 51(8):1093–102. doi: 10.1007/s00726-019-02754-x

35. Okada Y, Taniguchi H, Schimada C. High Concentration of GABA and High Glutamate Decarboxylase Activity in Rat Pancreatic Islets and Human Insulinoma. *Science* (1976) 194(4265):620–2. doi: 10.1126/science.185693

36. Reetz A, Solimena M, Matteoli M, Follì F, Takei K, De Camilli P, GABA and Pancreatic Beta-Cells: Co-localization of Glutamic Acid Decarboxylase (GAD) and GABA With Synaptic-like Microvesicles Suggests Their Role in GABA Storage and Secretion. *EUBIO J* (1991) 10(5):1275–84. doi: 10.1002/j.1460-2075.1991.tb08069.x

37. Unterreiner A, Xu J, Bhattacharjee A, Cabrera O, Hu C, Dai FF, et al. γ-Aminobutyric Acid Stimulates β-Cell Proliferation Through the Mtorc1/P70s6k Pathway, an Effect Amplified by ly49, a Novel γ-Aminobutyric Acid Type A Receptor Positive Allosteric Modulator. *Diabetes Obes Metab* (2020) 22(11):2021–31. doi: 10.1111/dom.14118

38. Feng AL, Xiang Y-Y, Gu L, Kaltsidis G, Feng Q, Lu W-Y, Paracrine GABA and Insulin Regulate Pancreatic Alpha Cell Proliferation in a Mouse Model of Type 1 Diabetes. *Diabetologia* (2017) 60(6):1033–42. doi: 10.1007/s00125-017-4239-x

39. Braun M, Ramacheya R, Bengtsson M, Clark A, Walker JN, Johnson PR, et al. Gamma-Aminobutyric Acid (GABA) Is an Autocrine Excitatory Transmitter in Human Pancreatic Beta-Cells. *Diabetes* (2010) 59(7):1694–701. doi: 10.2337/db09-0797

40. Dong H, Kumar M, Zhang Y, Gyulkhandanyan A, Xiang YY, Ye B, et al. Gamma-Aminobutyric Acid Up- and Downregulates Insulin Secretion From Beta Cells in Concert With Changes in Glucose Concentration. *Diabetologia* (2006) 49(4):697–705. doi: 10.1007/s00125-005-0123-1

41. Rachdi L, Maugein A, Pechberty S, Armanet M, Hamroune J, Ravassard P, et al. GABAB Receptors and Glucose Homeostasis: Evaluation in GABAB Group III Metabotropic Glutamate Receptor Positive Allosteric Modulator. *Cell Chem Biol* (2019) 26(6):1033–42. doi: 10.1016/j.chembiol.2019.05.011

42. Bonaventura MM, Catalano PN, Chaimson-Reig A, Arany E, Hill D, Bøttler B, et al. GABAB Receptors and Glucose Homeostasis: Evaluation in GABAB Receptor Knockout Mice. *Am J Physiol Endocrinol Metab* (2008) 294(1):E157–67. doi: 10.1152/ajpendo.00615.2006

43. Mengaz D, Hagan DW, Almaça J, Cianciaruso C, Rodríguez-Díaz R, Molina J, et al. Mechanism and Effects of Pulsatile GABA Secretion From Cytosolic Pools in the Human Beta Cell. *Nat Metab* (2019) 1(11):1110–26. doi: 10.1038/s42255-019-0135-7
44. Regnell SE, Lernmark A. Early Prediction of Autoimmune (Type 1) Diabetes. Diabetologia (2017) 60(8):1370–81. doi: 10.1007/s00125-017-4309-8

45. Prud’homme CJ, Glinka Y, Hasilo C, Paraskews S, Li X, Wang Q. GABA Protects Human Islet Cells Against the Deleterious Effects of Immunosuppressive Drugs and Exerts Immunoinhibitory Effects Alone. Transplantation (2013) 96(6):216–23. doi: 10.1097/TP.0b013e318292c4be

46. Betz H, Laube B. Glycine Receptors: Recent Insights Into Their Structural Organization and Functional Diversity. J Neurochem (2006) 97(6):1600–10. doi: 10.1111/j.1471-4159.2006.05908.x

47. Yan-Do R, Duong E, Manning Fox JE, Dai X, Suzuki K, Khan S, et al. A Global Human Pancreatic Islet Genomics Project Reveals Features of Islet Development and Function. Diabetes (2016) 65 (8):2311–21. doi: 10.2337/db15-1272

48. Li C, Liu C, Nissim I, Chen J, Chen P, Doliba N, et al. Regulation of Glucagon Secretion in Normal and Diabetic Human Islets by γ Hydroxybutyrate and Glycine. J Biol Chem (2013) 288(6):3938–51. doi: 10.1074/jbc.M112.385682

49. Caraiscos VB, Bonin RP, Newell JG, Czerwinska E, Macdonald JF, Orser BA. Insulin Increases the Potency of Glycine at Ionotropic Glycine Receptors. Mol Pharmacol (2007) 71(5):1277–87. doi: 10.1124/mol.106.033563

50. Gannon MC, Nuttall JA, Nuttall FQ. The Metabolic Response to Ingested Serine in the Brain and Peripheral Organs of Serine Racemase (Srr) Knockout Mice. Neurochem Int (2011) 97(6):853–9. doi: 10.1016/j.neuint.2011.08.017

51. Leman E, Baumann DC, Khakhbong B, Abrenica A, Miller RF, Aladjem EFU. Serine Racemase Is Expressed in Islets and Contributes to the Regulation of Glucose Homeostasis. Islets (2016) 8(6):195–206. doi: 10.1080/19382014.2016.1260797

52. Tsai F-J, Yang C-F, Chen C-C, Chuang L-M, Lu C-H, Chang C-T, et al. A Genome-Wide Association Study Identifies Susceptibility Variants for Type 2 Diabetes in Han Chinese. PLoS Genet (2010) 6(2):e1000847. doi: 10.1371/journal.pgen.1000847

53. Dong M, Gong Z-C, Dai X-P, Lei G-H, Lu H-B, Fan L, et al. Serine Racemase Rs391300 G/A Polymorphism Influences the Therapeutic Efficacy of Metformin in Chinese Patients With Diabetes Mellitus Type 2. Clin Exp Pharmacol Physiol (2011) 38(12):824–9. doi: 10.1111/j.1440-1618.2011.05600.x

54. Walther DJ, Stahlberg S, Vowinckel J. Novel Roles for Biogenic Monoamines: From Monoamines in Transglutaminase-Mediated Post-Translational Protein Modification to Monoaminonial Drug Reactions. FEBS J (2011) 278(24):4740–55. doi: 10.1111/j.1742-4658.2011.08347.x

55. Ng J, Papandreou A, Heales SJ, Kurian MA. Monoamine Neurotransmitter Disorders–Clinical Advances and Future Perspectives. Nat Rev Neurol (2015) 11(10):567–84. doi: 10.1038/nrneurol.2015.172

56. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous Bacteria From the Gut Microbiota Regulate Host Serotonin Biosynthesis. Cell (2015) 161(2):262–76. doi: 10.1016/j.cell.2015.02.047

57. D’Aniello G, Tolino A, D’Aniello A, Errico F, Fisher GH, Di Fiore MM. The Role of D-Aspartic Acid and N-Methyl-D-Aspartic Acid in the Regulation of Cerebral and Endocrine Tissues: Ontogeny, Biosynthesis and Release. Mol Neurobiol (2013) 50(1):1–11. doi: 10.1007/s12032-012-8341-4

58. Diaz-Flores M, Cruz M, Duran- Reyes G, Munguia-Miranda C, Loza-Rodriguez H, Pulido-Casas E, et al. Oral Supplementation With Glycine Reduces Oxidative Stress in Patients With Metabolic Syndrome, Improving Their Systolic Blood Pressure. Can J Physiol Pharmacol (2013) 91(10):855–60. doi: 10.1139/cjpp-2012-0341

59. Abdulbagi M, Wang L, Siddig O, Di B, Li B. D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets? Biomolecules (2021) 11(11):1716. doi: 10.3390/biom11111716

60. Wolosker H, D’Aniello A, Snyder SH. D-AAsp Deprivation in Neuropathic and Endocrine Tissues: Ontogeny, Biosynthesis and Release. Neuroscience (2000) 100(1):183–9. doi: 10.1016/S0306-4522(00)00023-1

61. D’Aniello G, Tolino A, D’Aniello A, Errico F, Fisher GH, Di Fiore MM. The Role of D-Aspartic Acid and N-Methyl-D-Aspartic Acid in the Regulation of Pancreatic β-Cell Function and Interactions: A Comprehensive Review. Endocr Rev (2000) 141(10):3862–70. doi: 10.1210/endo.141.10.7706

62. Santiago AR, Pereira TS, Garrido MJ, Cristo EJC, Ambrosio AF, Heras A, et al. Altered Serotonin (5-HT) 1D and 2A Receptor Expression may Contribute to Defective Insulin and Glucagon Secretion in Human Type 2 Diabetes. Peptides (2011) 31(3):299–304. doi: 10.1016/j.peptides.2010.07.008

63. Uvnäs-Moberg K, Ahlenius S, Alster P, Hillegaaert V. Effects of Selective Serotonin and Dopamine Agonists on Plasma Levels of Glucose, Insulin and Glucagon in the Rat. Neuroendocrinology (1996) 63(3):269–74. doi: 10.1159/000126970

64. Almaça J, Molina J, Menegaz D, Pronin AN, Tamayo A, Slepak V, et al. Human Beta Cells Produce and Release Serotonin to Inhibit Glucagon Secretion From Alpha Cells. Cell Rep (2016) 17(12):3281–91. doi: 10.1016/j.celrep.2016.11.072

65. Gromada J, Chabosseau P, Rutter GA. The γ-Cell in Diabetes Mellitus. Nat Rev Endocrinol (2018) 14(12):694–704. doi: 10.1038/s41574-018-0097-y

66. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and Cardiovascular Adverse Effects Associated With Antipsychotic Drugs. Nat Rev Cardiov (2018) 14(12):804–11. doi: 10.1038/s41574-018-0084-9

67. Rubi B, Macchi S, Motta E, Morfini L, Ravanelli A, Elia M, et al. Prostaglandin E1 Enhances β-Cell Secretion of Glucose but Depresses β-Cell Insulin Secretion in Patients With Type 2 Diabetes. J Cell Physiol (2012) 227(1):274–80. doi: 10.1002/jcp.22604

68. Benner H, Bulhuijen A, Medina A, Dekker Nittet M, Ottosson Laakso E, Essén S, et al. Altered Serotonin (5-HT) 1D and 2A Receptor Expression May Contribute to Defective Insulin and Glucagon Secretion in Human Type 2 Diabetes. Peptides (2017) 71:113–20. doi: 10.1016/j.peptides.2017.07.008

69. Aslanoglou D, Bertera S, Sánchez-Soto M, Benjamin Fre R, Lee J, Zong W, et al. Dopamine Regulates Pancreatic Glucagon and Insulin Secretion via Adrenergic and Dopaminergic Receptors. Transl Psychiatry (2011) 1(1):59. doi: 10.1038/tp.2011.20

70. Beaulieu J-M, Gainetdinov RR. The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacol Rev (2016) 63(1):182–217. doi: 10.1124/pr.110.002642
Pan et al. Transmitters in Pancreatic Islets

102. Ortiz-Alonso FJ, Herman WH, Zobel DL, Perry TJ, Smith MJ, Halter JB.  
100. Macotela Y, Triebel J, Clapp C. Time for a New Perspective on Prolactin in  
95. Va  
93. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
92. Rodriguez-Pena MS, Collins R, Woodard C, Spiegel AM. Decreased Insulin  
84. Chen Y, Hong F, Chen H, Fan R-F, Zhang X-L, Zhang Y, et al. Distinctive  
85. Fagerholm V, Grönroos T, Marjamäki P, Viljanen T, Scheinin M,  
89. Filipponi P, Gregorio F, Ferrandina C, Nicoletti I, Mannarelli C, Pippi R,  
88. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al.  
87. Rodriguez-Pena MS, Collins R, Woodard C, Spiegel AM. Decreased Insulin  
86. Chen Y, Hong F, Chen H, Fan R-F, Zhang X-L, Zhang Y, et al. Distinctive  
83. Fagerholm V, Grönroos T, Marjamäki P, Viljanen T, Scheinin M,  
82. Ortiz-Alonso FJ, Herman WH, Zobel DL, Perry TJ, Smith MJ, Halter JB.  
81. Martino L, Masini M, Bugliani M, Marselli L, Suleiman M, Boggi U, et al.  
80. Mannaioni PF, Masini E. The Release of Histamine by Free Radicals.  
79. Pini A, Obara I, Battell E, Chazot PL, Rosa AC. Histamine in Diabetes: Is It  
78. Garcia Barrado MJ, Iglesias Osma MC, Blanco EJ, Carretero Hernández M,  
77. Rosengren AH, Jokubka R, Toijar D, Granhall C, Hansson O, Li D-Q, et al.  
76. Redmon JB, Towle HC, Robertson RP. Regulation of Human Insulin Gene  
75. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
74. Va  
73. Saavedra JM, Dumas G, Zafra B, Bröer S, Valverde R, Korsching S, et al.  
72. Rodriguez-Pena MS, Collins R, Woodard C, Spiegel AM. Decreased Insulin  
71. Vázquez P, Robles AM, de Pablo F, Hernández-Sánchez C. Non-Neural  
70. de Souza CJ, Burkey BF. Beta 3-Adrenergic Receptor Agonists as Anti-Diabetic  
69. Ruiz B, Ljubicic S, Pournounomhamedi S, Carobbio S, Armanet M,  
68. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al.  
67. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al.  
66. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al.  
65. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al.  
64. Panula P, Nuutinen S. The Histaminergic Network in the Brain: Basic  
63. Kuznetsova A, Yu Y, Hollister-Lock J, Opare-Addo L, Rozzo A, Sadagurski  
62. Nakanura T, Yoshikawa T, Noguchi N, Sugawara A, Kasajima A, Sasano H,  
61. Nakamura T, Yoshikawa T, Noguchi N, Sugawara A, Kasaijima A, Sasano H,  
60. Tanimoto A, Matsuki T, Tomita T, Sasaguri M, Sasaguri Y, et al. Alpha-Adrenergic  
59. Filipponi P, Gregorio F, Ferrandina C, Nicoletti I, Mannarelli C, Pippi R,  
58. Redmon JB, Towle HC, Robertson RP. Regulation of Human Insulin Gene  
57. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
56. Va  
55. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
54. Va  
53. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
52. Va  
51. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
50. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
49. Va  
48. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
47. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
46. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
45. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
44. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
43. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
42. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
41. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
40. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
39. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
38. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
37. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
36. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
35. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
34. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
33. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
32. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
31. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
30. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
29. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
28. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
27. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
26. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
25. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
24. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
23. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
22. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
21. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
20. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
19. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
18. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
17. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
16. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
15. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
14. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
13. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
12. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
11. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
10. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
9. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
8. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
7. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
6. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
5. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
4. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
3. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
2. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood  
1. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced Blood
201. Nemeth ZH, Bleich D, Csóka B, Pacher P, Mabley JG, Himer L, et al. Adenosine Receptor Activation Ameliorates Type 1 Diabetes. *FASEB J* (2007) 21(10):2379–88. doi: 10.1096/fj.07-12213com

202. Anderson O, Adams BA, You D, Ellis GC, Gut P, Anderson RM, et al. Adenosine Signaling Promotes Regeneration of Pancreatic β Cells In Vivo. *Cell Metab* (2012) 15(6):885–94. doi: 10.1016/j.cmet.2012.04.018

203. Balasubramanian R, Ruiz de Azua I, Wess J, Jacobson KA. Activation of Distinct P2Y Receptor Subtypes Stimulates Insulin Secretion in MIN6 Mouse Pancreatic Beta Cells. *Biochem Pharmacol* (2010) 79(9):1317–26. doi: 10.1016/j.bcp.2009.12.026

204. Amisten S, Meidute-Abarevičienė S, Tan C, Olde B, Lundquist I, Salihi A, et al. ADP Mediates Inhibition of Insulin Secretion by Activation of P2Y13 Receptors in Mice. *Diabetologia* (2010) 53(9):1927–34. doi: 10.1007/s00125-009-1807-8

205. Coutinho-Silva R, Parsons M, Robson T, Lincoln J, Burnstock G. P2X and P2Y Purinoceptor Expression in Pancreas From Streptozotocin-Diabetic Rats. *Mol Cell Endocrinol* (2003) 204(1-2):141–54. doi: 10.1016/S0303-7207(03)00033-0

206. Balasubramanian R, Maruoka H, Jayasekara PS, Gao Z-G, Jacobson KA. AMP-Activated Protein Kinase as Regulator of P2Y6 Receptor-Induced Insulin Secretion in Mouse Pancreatic β-Cells. *Biochem Pharmacol* (2013) 85(7):991–8. doi: 10.1016/j.bcp.2012.11.029

207. Lee DH, Park K-S, Kim D-R, Lee J-W, Kong ID. Dual Effect of ATP on Glucose-Induced Insulin Secretion in HT-T15 Cells. *Pancreas* (2008) 37(3):302–8. doi: 10.1097/01.mpa.0000304308-6213

208. Parandeh F, Amisten S, Verma G, Mohammed Al-Amily L, Duner P, Sahli A. Inhibitory Effect of UDP-Glucose on cAMP Generation and Insulin Secretion. *J Biol Chem* (2020) 295(15):13524–52. doi: 10.1074/jbc.RA120.012929

209. Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B, et al. Update of P2Y Receptor Pharmacology: IUPHAR Review 27. *Br J Pharmacol* (2020) 177(11):2413–33. doi: 10.1111/bph.15005

210. Coutinho-Silva R, Parsons M, Robson T, Burnstock G. Changes in Expression of P2 Receptors in Rat and Mouse Pancreas During Development and Ageing. *Cell Tissue Res* (2001) 306(3):373–83. doi: 10.1007/s0044100100458

211. Silva AM, Rodrigues RJ, Tomé AR, Cunha RA, Misler S, Rosário LM, et al. Electrophysiological and Immunocytochemical Evidence for P2X Purinergic Receptors in Pancreatic Beta Cells. *Pancreas* (2008) 36(3):279–83. doi: 10.1097/MPA.0b013e31815a8473

212. Ohtani M, Ohura K, Oka T. Involvement of P2X7 Receptors in the Regulation of Insulin Secretion, Proliferation and Survival in Mouse Pancreatic β-Cells. *Cell Physiol Biochem* (2010) 26(3):302. doi: 10.1159/000331752

213. Milliken BT, Ellers C, Chepurny OG, Chichka KS, Sweet JB, Borner T, et al. Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss With Mitigated Nausea and Emesis. *J Med Chem* (2021) 64(2):1127–38. doi: 10.1021/acs.jmedchem.0c01783

214. Liu W, Lau HK, Son DO, Jin T, Yang Y, Zhang Z, et al. Combined Use of GABA and Sialitpin Promotes Human β-Cell Proliferation and Reduces Apoptosis. *J Endocrinol* (2021) 248(2):133–43. doi: 10.1530/JEO-20-0315

215. Bossart M, Wagner M, Elvert R, Evers T, Hübshle T, Kloeckener T, et al. Effects on Weight Loss and Glycemic Control With SAR441255, a Potent Unimolecular Peptide GLP-1/GIP/GCG Receptor Triagonist. *Cell Metab* (2022) 34(1):59–74. doi: 10.1016/j.cmet.2021.12.005

216. Lu VB, Rieva J, OFlaherty EA, Smith CA, Pais R, Pattison LA, et al. Adenosine Triphosphate Is Co-Secreted With Glucagon-Like Peptide-1 to Modulate Intestinal Enterocytes and Afferent Neurons. *Nat Commun* (2019) 10(1):1029. doi: 10.1038/s41467-019-09945-9

217. Payne SC, Ward G, MacIsaac RJ, Hyakumura T, Fallon JB, Villalobos J. Differential Effects of Vagus Nerve Stimulation Strategies on Glycemia and Pancreatic Secretions. *Physiol Rep* (2020) 8(11):e14479. doi: 10.1111/phy2.14479

218. Yin J, Ji F, Gharabani P, Chen JD. Vagal Nerve Stimulation for Glycemic Control in a Rodent Model of Type 2 Diabetes. *Obes Surg* (2019) 29(9):2869–77. doi: 10.1007/s11695-019-03901-9

219. Chikora SA, Tounli J, Herrera MF, Kulseng B, Brancatisano R, Kow L, et al. Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients With Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study. *Obes Surg* (2016) 26(5):1021–8. doi: 10.1007/s11695-015-1914-1

**Conflict of Interest:** NT has worked on clinical trials funded by Huadong Medicine Group Company Limited, and received lecture fees from Novo Nordisk. However, these interests will not impair justice and scientific nature of this study.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in
